Dyslipidemia Therapeutics Market: Overview
Dyslipidemia, a key risk factor for cardiovascular disease (CVD), poses high health burden to the developed world, thus, propelling the need for effective therapies that are well tolerated. The condition is characterized by low-density lipoprotein-cholesterol (LDL-C) and triglyceride concentrations. Statins have long been preferred in dyslipidemia therapeutics market for dramatically reducing LDL-C levels, and hence the CVD risks. However, when these are used as sole therapies, they lack effectiveness. According to a research in 2012, these have been found to be ineffective in 5% to 10% of people. More of such research have found poor tolerability of statins, which has been widening the unmet need in the dyslipidemia therapeutics market.
As a result, the dyslipidemia therapeutics market is seeing strides on the back of efforts by various research and development activities related to blockbuster therapies. Some of the key non-statins witnessing the potential in the market are PCSK9 inhibitors, cholesterol absorption inhibitors, bile acid resins, fibrate, and combinations drugs. Major distribution channels witnessing investments in the dyslipidemia therapeutics market are hospitals pharmacies, drug stores, retail stores, and mail order pharmacies.
Do you want to assess potential implications of COVID-19 pandemic on your business and boost your preparedness? Grab an exclusive PDF Brochure for this report!
Dyslipidemia Therapeutics Market: Key Trends
The drive for novel LDL-C-lowering agents is a key trend boosting the revenue potential in the dyslipidemia therapeutics market. Among the various key therapies, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have attracted attention as a part of next-gen blockbuster therapies. Research on novel cholesterol-lowering therapies has spurred revenue streams in the dyslipidemia therapeutics market. The demand for such therapies is prominent in patients with familial hypercholesterolemia.
Marked risk of coronary heart disease in populations of developed countries is also bolstering the demand for expanding the drug pipeline. Monoclonal antibodies have also shown some potential in the dyslipidemia therapeutics market, due to their high tolerability. CSK9 monoclonal antibodies and ezetimibe are examples.
Dyslipidemia Therapeutics Market: Competitive Analysis and Key Developments
Over the past few years, randomized trials on lowering LDL cholesterol concentrations have shaped the competitive dynamics in the dyslipidemia therapeutics market. Cholesterol Treatment Trialists' (CTT) Collaborators have led to higher efficacy and safety of cholesterol-lowering treatment reduces the incidence of coronary heart disease (CHD). For instance, such interventions could lead to 22% relative reduction in many vascular events per mmol/L reduction in LDL-C, underscoring a strong link between the two.
In another vein, there is a need for more intensive treatment in dyslipidemia therapeutics market which should include not just LDL-C lowering approach. According to a recent trail finding of REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl - Intervention Trial) subgroup analysis in the European Heart Journal, ethyl eicosapentaenoic acid could improve atherosclerotic cardiovascular disease (ASCVD) outcomes.
Are you a start-up willing to make it big in business? Grab an exclusive Sample for this report
Additionally, in statin-based therapies, researchers need to put strong focus on elevated baseline triglycerides. Over and above this therapy, icosapent ethyl has benefitted patients with ASCVD. Thus, regulatory guidelines in the U.S. and Europe support icosapent ethyl as a Class IIa and Class IB therapy in the dyslipidemia therapeutics market.
Some of the well-entrenched players in the dyslipidemia therapeutics market are Novartis AG, Abbott Laboratories, Mylan, Novelion Therapeutics, Sanofi, Amgen, Pfizer, Merck & Co., and Kowa Pharmaceuticals America, Inc.
Dyslipidemia Therapeutics Market: Regional Assessment
North America and Europe are key geographic markets. Prevalence of coronary heart disease in these regions has led to the demand for novel cholesterol-lowering therapies for reducing atherosclerotic cardiovascular disease (ASCVD) outcomes. Strides being made in acute coronary syndrome in the U.S. are bolstering the revenue potential of these in the global dyslipidemia therapeutics market. Extensive research in therapies with increased efficacy and tolerability has kept the North America market increasingly lucrative over the past ten years.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.